Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Liverpool Hospital /ID# 227723, Liverpool

Austin Health /ID# 227717, Heidelberg

UPMC Hillman Cancer Ctr /ID# 228048, Pittsburgh

University of Pennsylvania /ID# 227024, Philadelphia

Istituto Clinico Humanitas /ID# 226948, Rozzano

ASST Grande Ospedale Metropolitano Niguarda /ID# 226952, Milan

Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 227748, Hamburg

University of Virginia Health /ID# 227363, Charlottesville

Hospital Universitario Fundacion Jimenez Diaz /ID# 227771, Madrid

Hospital Universitario Virgen de la Victoria /ID# 227770, Málaga

University of Alabama at Birmingham - Main /ID# 227071, Birmingham

IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 226950, Bologna

Norton Cancer Institute - St Matthews /ID# 228378, Louisville

Marien Hospital Duesseldorf /ID# 227751, Düsseldorf

University of Michigan /ID# 227030, Ann Arbor

Hadassah Medical Center-Hebrew University /ID# 227275, Jerusalem

Rabin Medical Center /ID# 227738, Petah Tikva

The Chaim Sheba Medical Center /ID# 227389, Ramat Gan

Tel Aviv Sourasky Medical Center /ID# 227387, Tel Aviv

Massachusetts General Hospital /ID# 227273, Boston

Beth Israel Deaconess Medical Center /ID# 231083, Boston

MD Anderson Cancer Center at Texas Medical Center /ID# 227019, Houston

Universitaetsklinikum Leipzig /ID# 227750, Leipzig

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 227749, Dresden

National Cancer Center Hospital East /ID# 232498, Kashiwa-shi

University of Fukui Hospital /ID# 232466, Yoshida-gun

Kyushu University Hospital /ID# 232564, Fukuoka

Yamagata University Hospital /ID# 232451, Yamagata

Hospital Clinic de Barcelona /ID# 227772, Barcelona